3
Announcements
Trials
Browse
Landscape
Status
Terminated
2
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
151
Leukemia
138
Leukemia, Myeloid, Acute
127
Myelodysplastic Syndromes
106
Precursor Cell Lymphoblastic Leukemia-Lymphoma
103
Lymphoma
87
Lymphoma, Non-Hodgkin
86
Multiple Myeloma
84
Hodgkin Disease
81
Lymphoma, Mantle-Cell
71
Lymphoma, Follicular
68
Lymphoma, Large B-Cell, Diffuse
60
Congenital Abnormalities
59
Myeloproliferative Disorders
58
Lymphoma, B-Cell, Marginal Zone
58
Leukemia, Myeloid, Chronic-Phase
56
Leukemia, Myelomonocytic, Chronic
52
Leukemia, Myeloid, Accelerated Phase
50
Burkitt Lymphoma
50
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
46
Lymphoma, Large-Cell, Immunoblastic
43
Anemia, Refractory, with Excess of Blasts
42
Waldenstrom Macroglobulinemia
41
Blast Crisis
40
Primary Myelofibrosis
38
Melanoma
35
Recurrence
34
Neoplasms, Plasma Cell
34
Dendritic Cell Sarcoma, Interdigitating
30
Lymphoma, T-Cell, Cutaneous
29
Interventions
fludarabine
2
fludarabine phosphate
1
Thiotepa
1
Melphalan
1
Erythrocyte Count
1
Clofarabine
1
Blood Transfusion
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Thalassemia
×
fludarabine phosphate
×
Clear all
NCT01316549
2021-10-04
HCT
University of California, San Francisco
Completed
67 enrolled